Experimental drug could fight slow-growing cancers OCRegister In one trial, 220 patients with recurrent chronic lymphocytic leukemia were given an intravenous drug called rituximab, a standard treatment. Half of participants were also given idelalisib twice a day in pill form. • Overall, 81 percent of patients ... |
